Singh N, Yu V L
Infectious Disease Section, VA Medical Center, University, Pittsburgh, Pennsylvania 15240.
Clin Infect Dis. 1992 Jan;14(1):156-61. doi: 10.1093/clinids/14.1.156.
During the past decade, Mycobacterium chelonae has been recognized with increasing frequency as a pulmonary pathogen. A review of previously reported cases reveals that most patients with pulmonary infections due to M. chelonae are nonimmunosuppressed but have underlying chronic lung disease. The infection is notably absent among blacks. M. chelonae organisms are characterized by a high degree of in vitro resistance to antituberculous drugs, and attempts at eradicating the organism through chemotherapy have been largely unsuccessful. The case of a 63-year-old previously healthy woman with progressive bilateral pulmonary disease due to M. chelonae is reported; she was treated successfully with a combination of cefoxitin and orally administered ciprofloxacin. Our experience supports the use of quinolones in combination with other active agents for the treatment of pulmonary infection due to M. chelonae.
在过去十年中，龟分枝杆菌作为肺部病原体被越来越频繁地发现。对既往报道病例的回顾显示，大多数因龟分枝杆菌引起肺部感染的患者并非免疫抑制患者，但都有潜在的慢性肺部疾病。值得注意的是，黑人中不存在这种感染。龟分枝杆菌具有高度的体外抗结核药物耐药性，通过化疗根除该菌的尝试大多未成功。本文报道了一名63岁既往健康的女性因龟分枝杆菌感染导致进行性双侧肺部疾病的病例；她通过头孢西丁和口服环丙沙星联合治疗获得成功。我们的经验支持喹诺酮类药物与其他活性药物联合用于治疗龟分枝杆菌引起的肺部感染。
